{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T10:41:48Z","timestamp":1794220908676,"version":"4.8.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"am","delay-in-days":300,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Aging"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.neurobiolaging.2022.07.015","type":"journal-article","created":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T02:21:24Z","timestamp":1664590884000},"page":"15-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["CSF peptides from VGF and other markers enhance prediction of MCI to AD progression using the ATN framework"],"prefix":"10.1016","volume":"121","author":[{"given":"Daniel A.","family":"Llano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Devanarayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viswanath","family":"Devanarayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0001","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jalz.2015.05.005","article-title":"Alzheimer's Disease Neuroimaging Initiative 2 clinical core: progress and plans","volume":"11","author":"Aisen","year":"2015","journal-title":"Alzheimer's & Dementia"},{"issue":"34","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0002","doi-asserted-by":"crossref","first-page":"10800","DOI":"10.1523\/JNEUROSCI.23-34-10800.2003","article-title":"Brain-derived neurotrophic factor-induced gene expression reveals novel actions of VGF in hippocampal synaptic plasticity","volume":"23","author":"Alder","year":"2003","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0003","first-page":"e12026","article-title":"Prognostic value of ATN Alzheimer biomarkers: 60-month follow-up results from the Argentine Alzheimer's Disease Neuroimaging Initiative","volume":"12","author":"Allegri","year":"2020","journal-title":"Alzheimer's & Dementia: Diagnosis, Assess. & Dis. Monitoring"},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0004","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0197-4580(00)00094-4","article-title":"Microglia, amyloid and dementia in Alzheimer disease: a correlative study","volume":"21","author":"Arends","year":"2000","journal-title":"Neurobiol aging"},{"issue":"6","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0005","doi-asserted-by":"crossref","first-page":"e9356","DOI":"10.15252\/msb.20199356","article-title":"Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease","volume":"16","author":"Bader","year":"2020","journal-title":"Molecular syst. biol"},{"issue":"4","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0006","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","article-title":"Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010","volume":"71","author":"Beach","year":"2012","journal-title":"J. neuropathol. Exp. Neurol."},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0007","first-page":"1","article-title":"Multiscale causal networks identify VGF as a key regulator of Alzheimer's disease","volume":"11","author":"Beckmann","year":"2020","journal-title":"Natr. commun."},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-2094-7-34","article-title":"In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases","volume":"7","author":"Bonneh-Barkay","year":"2010","journal-title":"J. neuroinflammation"},{"issue":"39","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0009","doi-asserted-by":"crossref","first-page":"9857","DOI":"10.1523\/JNEUROSCI.3145-08.2008","article-title":"The neurotrophin-inducible gene Vgf regulates hippocampal function and behavior through a brain-derived neurotrophic factor-dependent mechanism","volume":"28","author":"Bozdagi","year":"2008","journal-title":"J. Neurosci."},{"issue":"8","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0010","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/pmic.200300470","article-title":"A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease","volume":"3","author":"Carrette","year":"2003","journal-title":"Proteomics"},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-83601-6","article-title":"Plasma osteopontin as a biomarker of Alzheimer's disease and vascular cognitive impairment","volume":"11","author":"Chai","year":"2021","journal-title":"Sci. rep."},{"key":"10.1016\/j.neurobiolaging.2022.07.015_bib0012","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3389\/fncel.2019.00575","article-title":"The role of neuronal pentraxin 2 (NP2) in regulating glutamatergic signaling and neuropathology","volume":"13","author":"Chapman","year":"2020","journal-title":"Front. cellular neurosci."},{"issue":"6","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0013","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1469-7580.2010.01309.x","article-title":"Distribution of VGF peptides in the human cortex and their selective changes in Parkinson's and Alzheimer's diseases","volume":"217","author":"Cocco","year":"2010","journal-title":"J. anatomy"},{"issue":"4","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0014","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3233\/JAD-2010-1309","article-title":"Osteopontin is increased in the cerebrospinal fluid of patients with Alzheimer's disease and its levels correlate with cognitive decline","volume":"19","author":"Comi","year":"2010","journal-title":"J. Alzheimer's Disease"},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-021-00817-4","article-title":"Prognostic value of amyloid\/tau\/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer's disease","volume":"13","author":"Delmotte","year":"2021","journal-title":"Alzheimer's res. therapy"},{"issue":"2","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0016","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3233\/JAD-180905","article-title":"Identification of a Simple and Novel Cut-Point Based CSF and MRI Signature for Predicting Alzheimer's Disease Progression That Reinforces the 2018 NIA-AA research framework","volume":"68","author":"Devanarayan","year":"2019","journal-title":"Journal of Alzheimer's Disease"},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-020-0357-x","article-title":"VGF-derived peptide TLQP-21 modulates microglial function through C3aR1 signaling pathways and reduces neuropathology in 5xFAD mice","volume":"15","author":"El Gaamouch","year":"2020","journal-title":"Mol. neurodegeneration"},{"issue":"7","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0018","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jalz.2015.05.010","article-title":"Brain collection, standardized neuropathologic assessment, and comorbidity in Alzheimer's Disease Neuroimaging Initiative 2 participants","volume":"11","author":"Franklin","year":"2015","journal-title":"Alzheimer's & Dementia"},{"issue":"4","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0019","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.celrep.2019.03.099","article-title":"The major risk factors for Alzheimer's disease: age, sex, and genes modulate the microglia response to A\u03b2 plaques","volume":"27","author":"Frigerio","year":"2019","journal-title":"Cell rep."},{"key":"10.1016\/j.neurobiolaging.2022.07.015_bib0020","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.trci.2019.11.002","article-title":"Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease","volume":"5","author":"Galasko","year":"2019","journal-title":"Alzheimer's & Dementia: Transl. Res. & Clin Inter."},{"key":"10.1016\/j.neurobiolaging.2022.07.015_bib0021","first-page":"e105","article-title":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019","year":"2022","journal-title":"The Lancet Public Health"},{"issue":"8","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135365","article-title":"High resolution discovery proteomics reveals candidate disease progression markers of Alzheimer's disease in human cerebrospinal fluid","volume":"10","author":"Hendrickson","year":"2015","journal-title":"PloS one"},{"issue":"43","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0023","doi-asserted-by":"crossref","first-page":"eaaz9360","DOI":"10.1126\/sciadv.aaz9360","article-title":"Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer's disease","volume":"6","author":"Higginbotham","year":"2020","journal-title":"Sci. adv."},{"issue":"2","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0024","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1021\/pr501076j","article-title":"An integrated workflow for multiplex CSF proteomics and peptidomics - Identification of candidate cerebrospinal fluid biomarkers of Alzheimer\u2019s disease","volume":"14","author":"H\u00f6ltt\u00e4","year":"2014","journal-title":"J. proteome res."},{"key":"10.1016\/j.neurobiolaging.2022.07.015_bib0025","first-page":"1","article-title":"Biofluid biomarkers of Alzheimer's disease: progress, problems, and perspectives","author":"Huang","year":"2022","journal-title":"Neurosci. Bulletin"},{"issue":"4","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0026","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer's & Dementia"},{"issue":"5","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0027","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers","volume":"87","author":"Jack","year":"2016","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0028","doi-asserted-by":"crossref","first-page":"e26540","DOI":"10.1371\/journal.pone.0026540","article-title":"Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers","volume":"6","author":"Jahn","year":"2011","journal-title":"PloS one"},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0029","first-page":"1","article-title":"Proteome-wide characterization of signalling interactions in the hippocampal CA4\/DG subfield of patients with Alzheimer's disease","volume":"5","author":"Kim","year":"2015","journal-title":"Scientific reports"},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0030","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41467-019-13901-z","article-title":"Clinically accurate diagnosis of Alzheimer's disease via multiplexed sensing of core biomarkers in human plasma","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0031","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1002\/alz.12353","article-title":"Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer\u2019s disease","volume":"17","author":"Libiger","year":"2021","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"4","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0032","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/WAD.0b013e31823b2728","article-title":"Cerebrospinal fluid cytokine dynamics differ between Alzheimer's Disease patients and elderly controls","volume":"26","author":"Llano","year":"2012","journal-title":"Alzheimer Dis. Assoc. Disorders"},{"issue":"8","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182098","article-title":"A multivariate predictive modeling approach reveals a novel CSF peptide signature for both Alzheimer's Disease state classification and for predicting future disease progression","volume":"12","author":"Llano","year":"2017","journal-title":"PloS one"},{"issue":"4","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0034","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/WAD.0000000000000328","article-title":"VGF in cerebrospinal fluid combined with conventional biomarkers enhances prediction of conversion from MCI to AD","volume":"33","author":"Llano","year":"2019","journal-title":"Alzheimer Dis. Assoc. Dis."},{"issue":"7","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0035","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"issue":"21","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0036","doi-asserted-by":"crossref","first-page":"e2065","DOI":"10.1212\/WNL.0000000000012853","article-title":"CSF synaptic biomarkers in the preclinical stage of alzheimer disease and their association with MRI and PET: a cross-sectional study","volume":"97","author":"Mil\u00e0-Alom\u00e0","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-020-1723-x","article-title":"Frontal cortex chitinase and pentraxin neuroinflammatory alterations during the progression of Alzheimer's disease","volume":"17","author":"Moreno-Rodriguez","year":"2020","journal-title":"J. neuroinflammation"},{"issue":"4","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0038","doi-asserted-by":"crossref","first-page":"fcab261","DOI":"10.1093\/braincomms\/fcab261","article-title":"VGF as a biomarker and therapeutic target in neurodegenerative and psychiatric diseases","volume":"3","author":"Quinn","year":"2021","journal-title":"Brain Commun."},{"issue":"12","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0039","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/prca.201500150","article-title":"CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer's disease","volume":"10","author":"Remnest\u00e5l","year":"2016","journal-title":"PROTEOMICS\u2013Clin. Appl."},{"issue":"2","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0040","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.expneurol.2005.08.002","article-title":"Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF","volume":"196","author":"R\u00fcetschi","year":"2005","journal-title":"Exp. neurol"},{"issue":"Suppl 1","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0041","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40120-017-0069-5","article-title":"Increasing precision of clinical diagnosis of alzheimer's disease using a combined algorithm incorporating clinical and novel biomarker data","volume":"6","author":"Sabbagh","year":"2017","journal-title":"Neurol. therapy"},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0042","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jalz.2018.08.006","article-title":"Elevated CSF GAP-43 is Alzheimer's disease specific and associated with tau and amyloid pathology","volume":"15","author":"Sandelius","year":"2019","journal-title":"Alzheimer's & Dementia"},{"key":"10.1016\/j.neurobiolaging.2022.07.015_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2019.146305","article-title":"Sex difference in CHI3L1 expression levels in human brain aging and in Alzheimer's disease","volume":"1720","author":"Sanfilippo","year":"2019","journal-title":"Brain res."},{"issue":"8","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0044","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2174\/138620705774962391","article-title":"Identification of novel biomarker candidates by differential peptidomics analysis of cerebrospinal fluid in Alzheimer's disease","volume":"8","author":"Selle","year":"2005","journal-title":"Combinatorial chem high throughput screening"},{"issue":"4","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0045","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000051268","article-title":"The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process","volume":"12","author":"Sj\u00f6gren","year":"2001","journal-title":"Dementia and geriatric cognitive disorders"},{"issue":"5","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0046","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s007020070079","article-title":"CSF levels of tau, \u03b2-amyloid 1\u201342 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging","volume":"107","author":"Sj\u00f6gren","year":"2000","journal-title":"J neural transmission"},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0047","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0306-4522(97)00280-7","article-title":"The messenger RNA encoding VGF, a neuronal peptide precursor, is rapidly regulated in the rat central nervous system by neuronal activity, seizure and lesion","volume":"82","author":"Snyder","year":"1997","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0048","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/(SICI)1096-9861(19980427)394:1<91::AID-CNE7>3.0.CO;2-C","article-title":"Expression of VGF mRNA in the adult rat central nervous system","volume":"394","author":"Snyder","year":"1998","journal-title":"J Comparative Neurol"},{"key":"10.1016\/j.neurobiolaging.2022.07.015_bib0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/615745","article-title":"Elevated osteopontin levels in mild cognitive impairment and Alzheimer\u2019s disease","author":"Sun","year":"2013","journal-title":"Mediators of inflammation"},{"key":"10.1016\/j.neurobiolaging.2022.07.015_bib0050","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bbi.2016.07.148","article-title":"Neuronal Pentraxin 2 predicts medial temporal atrophy and memory decline across the Alzheimer's disease spectrum","volume":"58","author":"Swanson","year":"2016","journal-title":"Brain, behav, and immunity"},{"issue":"3","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0051","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.scr.2014.03.005","article-title":"VGF (TLQP-62)-induced neurogenesis targets early phase neural progenitor cells in the adult hippocampus and requires glutamate and BDNF signaling","volume":"12","author":"Thakker-Varia","year":"2014","journal-title":"Stem cell res."},{"issue":"45","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0052","doi-asserted-by":"crossref","first-page":"12156","DOI":"10.1523\/JNEUROSCI.1898-07.2007","article-title":"The neuropeptide VGF produces antidepressant-like behavioral effects and enhances proliferation in the hippocampus","volume":"27","author":"Thakker-Varia","year":"2007","journal-title":"J. Neurosci."},{"issue":"8","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0053","doi-asserted-by":"crossref","first-page":"e953","DOI":"10.1212\/WNL.0000000000010131","article-title":"Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease","volume":"95","author":"Tible","year":"2020","journal-title":"Neurology"},{"issue":"19","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0054","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.3390\/ijms20194674","article-title":"VGF peptides in cerebrospinal fluid of patients with dementia with Lewy bodies","volume":"20","author":"van Steenoven","year":"2019","journal-title":"Int. j. mol. Sci."},{"key":"10.1016\/j.neurobiolaging.2022.07.015_bib0055","unstructured":"Watson, C., Seyfried, N.T., Levey, A.I., 2021. Targeted Proteomics Analysis of CSF by Mass Spectrometry. https:\/\/ida.loni.usc.edu\/download\/files\/study\/ec031cc8-89cd-4c24-ab13-81d20893a761\/file\/adni\/ADNI_Emory_CSF_Targeted_MS_Methods_20210928.pdf Accessed December 15, 2021."},{"key":"10.1016\/j.neurobiolaging.2022.07.015_bib0056","doi-asserted-by":"crossref","first-page":"e23798","DOI":"10.7554\/eLife.23798","article-title":"NPTX2 and cognitive dysfunction in Alzheimer's Disease","volume":"6","author":"Xiao","year":"2017","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0057","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12539-019-00353-8","article-title":"Identification of key regulatory genes and pathways in prefrontal cortex of Alzheimer's disease","volume":"12","author":"Yang","year":"2020","journal-title":"Interdiscipl. Sci.: Computational Life Sci."},{"issue":"1","key":"10.1016\/j.neurobiolaging.2022.07.015_bib0058","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-018-0127-7","article-title":"Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer's disease","volume":"7","author":"Zhang","year":"2018","journal-title":"Transl. neurodegeneration"},{"key":"10.1016\/j.neurobiolaging.2022.07.015_bib0059","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12014-020-09285-8","article-title":"Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer's disease","volume":"17","author":"Zhou","year":"2020","journal-title":"Clin. proteomics"}],"container-title":["Neurobiology of Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458022002068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458022002068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T11:42:28Z","timestamp":1759318948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197458022002068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":59,"alternative-id":["S0197458022002068"],"URL":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2022.07.015","relation":{},"ISSN":["0197-4580"],"issn-type":[{"value":"0197-4580","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CSF peptides from VGF and other markers enhance prediction of MCI to AD progression using the ATN framework","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Aging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2022.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}